You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
McKesson
Mallinckrodt

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,284,537

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,284,537
Title: Immortalized human corneal epithelial cell line
Abstract:Immortalized human cornea). epithelial cell line capable of becoming stratified, and capable of expressing (1) metabolic markers specific for non-immortalized human epithelial cells such as vimentin, cytokeratins, connections between the cells, cytochrome P450s, a glutathione-S-transferase, Cu/Zn-superoxide dismutase, glutathione peroxidase, aldehyde reductase and catalase; (2) metabolic differentiation markers specific for non-immortalized human cornea). epithelial cells such as the cytokeratin of 64 kfl, the glutathione-stransferase hGST 5.8, and the profile of cytokines and growth factors comprising the compounds TNF.alpha., IL-1.beta., IL-1.alpha., IL-6, IL-8, GM CSF-.beta., IL-ra, TGF-.beta.1, TGF-.beta.2, TGF.alpha., EGF, PDGF-.beta.; (3) and markers specific for an inflammatory reaction such as collagenase I, the bradykinin, histamine and PAF receptors, and the system for transduction of an inflammatory signal by the phosphoinositides. Process for identifying the mutagenic, toxic or beneficial effect of an agent on the metabolism of the corneal cells, in which (1) an agent suspected of being a mutagenic, toxic or beneficial agent for the metabolism of the cells of the human cornea is reacted, cultured or brought into contact with a culture comprising a cell line according to the invention, and (2) the effects of the said agent on the said cell line are determined or measured.
Inventor(s): Offord Cavin; Elizabeth (Poliez-Pittet, CH), Pfeifer; Andrea M. A. (St-Legier, CH), Sharif; Najam A. (Arlington, TX), Tromvoukis; Yvonne (Mollie-Margot, CH)
Assignee: Nestec S.A. (Vevey, CH)
Application Number:08/997,588
Patent Claims:see list of patent claims

Details for Patent 6,284,537

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Nestec S.A. (Vevey, CH) 2016-12-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
McKesson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.